Sandoz said on Monday that it has successfully submitted its Biologics License Application (BLA) with the US Food and Drug Administration (FDA) under the 351 (k) pathway for proposed biosimilar adalimumab to the reference medicine, Humira.
According to the company, adalimumab is indicated for the treatment of a number of inflammatory diseases including rheumatoid arthritis, plaque psoriasis, Crohn's disease and ulcerative colitis.
The company stated the comprehensive data package submitted to the US FDA comprises of analytical, preclinical and clinical data from the proposed biosimilar adalimumab.
In conjunction, the clinical studies submitted to the US FDA include a pharmacokinetic study in healthy volunteers and a Phase III confirmatory safety and efficacy study in patients with moderate to severe chronic plaque-type psoriasis (ADACCESS). The study is expected to demonstrate that the company's proposed biosimilar adalimumab matches the reference biologic in terms of safety, efficacy and quality.
Sandoz is the first global healthcare company to establish a leading position in both innovative and off-patent medicines and is part of Novartis.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial